Genmab — August 2020
-
x med 12 og x herefter med 2(måske 2.3 ROW) så har du groft sagt resultatet for i år, hvilket springer samtlige estimater og vel betyder at der er vildt meget upside-risiko i aktien, som medfører at Nordea må opjustere med 7.75, mens vi andre åbner en flaske "sprudlewasser".
-
Det vel også en MEGET grov udregning McJ?
-
Recepttallet i US er ikke lig med det faktiske salg. Så det ligger uden 218.
-
under
-
so on Cami-t - in terms of Cami, the Hodgkin lymphoma program, we have -- we hope to be able to update at ASH. We don't know yet, of course, if our asset is accepted, but we are playing out data at ASH from the Cami trial, on the 47 patients that were enrolled through March.
-
twitter:
@semodough
Baml $HZNP US: Horizon Therapeutics - Encouraging Symphony sales trend for Tepezza in July - BUY-July Symphony sales for Tepezza (+24% m/m) imply a wide range between $217m and $339m for 3Q sales assuming 17% and 10% m/m growth in August and September. -
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind